AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 7910230
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment with PSK (protein‐bound polysaccharide)
Trial: 7910230
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment alone (mitomycin plus oral fluorouracil)
Trial: 2967433
Drug: Aspirin-dipyridamole combination
RxNorm normalized name: aspirin / dipyridamole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin-dipyridamole combination (330 mg-75 mg) given three times daily, with intravenous dipyridamole at 10 mg per hour for 24 hours before PTCA.
Trial: 2967433
Drug: Aspirin-dipyridamole combination
RxNorm normalized name: aspirin / dipyridamole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin-dipyridamole combination (active drug)
Trial: 31959416
Drug: Insulin and
RxNorm normalized name: Isophane insulin and porcine regular insulin only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin and heparin treatment with aggressive fluid resuscitation
Trial: 26220439
Drug: Plum-blossom needle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plum-blossom needle therapy
Trial: 23897332
Drug: Lidocaine in
RxNorm normalized name: lidocaine Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine in infiltration solution
Trial: 23897332
Drug: Control (infiltration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (infiltration solution without lidocaine)
Trial: 14620619
Drug: Standard triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard triple therapy plus bovine lactoferrin (group A)
Trial: 14620619
Drug: Standard triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard triple therapy (group B)
Trial: 14620619
Drug: 10-day standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-day standard triple therapy (group C)
Trial: 7036283
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg poly A‐poly U i.v. once a week for 6 weeks
Trial: 29203151
Drug: ADV6209 (2mg/ml
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADV6209 (2mg/ml oral solution of midazolam containing cyclodextrin)
Trial: 20415574
Drug: Delayed ART
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Delayed ART (after 10 weeks of treatment with fluconazole alone)
Trial: 12351537
Drug: Nitroglycerin (NTG)
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerin (NTG) patch administered the day before embryo transfer and continued until pregnancy test results or menstruation
Trial: 7781399
Drug: Concurrent chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent chemotherapy and RT
Trial: 7781399
Drug: Combined modality
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined modality of RT and chemotherapy
Trial: 11850096
Drug: Insulin treatment
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin treatment for 4 weeks
Trial: 6108779
Drug: Lorazepam 2
RxNorm normalized name: lorazepam 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorazepam 2 mg + Morphine 5 mg
Trial: 6108779
Drug: Lorazepam 4
RxNorm normalized name: lorazepam 4 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorazepam 4 mg + Morphine 5 mg
Trial: 6108779
Drug: Lorazepam 2
RxNorm normalized name: lorazepam 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorazepam 2 mg and 4 mg
Trial: 6653648
Drug: Diazoxide 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazoxide 150 mg
Trial: 6653648
Drug: Labetalol 50
RxNorm normalized name: labetalol 500 mg/500 mL-NaCl 0.9% intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Labetalol 50 mg
Trial: 30915467
Drug: Lipid-based nutrient
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid-based nutrient supplement (LNS) provided daily during pregnancy and first 6 months postpartum, and to infants from age 6 to 18 months.
Trial: 30915467
Drug: Non-LNS group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-LNS group received daily iron and folic acid or multiple micronutrients during pregnancy and first 6 months postpartum, with no infant supplementation.
Trial: 27085586
Drug: PF‐06260414 (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF‐06260414 (1 to 400 mg for SAD, 3 to 100 mg BID for MAD, 60 mg once-daily, 30 mg BID for Japanese cohort)
Trial: 27085586
Drug: PF‐06260414 (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF‐06260414 (100 mg BID)
Trial: 18612863
Drug: Clinician-assisted computerized
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinician-assisted computerized cognitive behavioural treatment programme
Trial: 16038711
Drug: No antiplatelet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antiplatelet therapy (control group)
Trial: 16038711
Drug: No oral
RxNorm normalized name: Beano Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No oral anticoagulants (control group)
Trial: 31244487
Drug: TheraSling therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TheraSling therapy (TST) combined with neuromuscular facilitation technique
Trial: 25072405
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy administered over the telephone (CBT-T)
Trial: 25072405
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy administered in-person (CBT-IP)
Trial: 16499515
Drug: Buprenorphine depot
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine depot injection (58 mg)
Trial: 12910861
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin (Fraxiparin)
Trial: 10884451
Drug: rTPA (0.9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rTPA (0.9 mg/kg IV)
Trial: 9333327
Drug: Low-dose dopamine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose dopamine (1-3 μg x kg-1 x min-1)
Trial: 9333327
Drug: Routine administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Routine administration of low-dose dopamine
Trial: 8480823
Drug: Multicomponent behavioral
RxNorm normalized name: meningococcus B, multicomponent vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multicomponent behavioral treatment
Trial: 8480823
Drug: Drug abuse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug abuse counseling
Trial: 28334979
Drug: Clinical medication
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical medication reviews (CMR)
Trial: 18584240
Drug: Low-dose TACE
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose TACE (2 mg mitomycin C, 10 mg epirubicin, 100 mg carboplatin)
Trial: 18584240
Drug: High-dose TACE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose TACE (10 mg mitomycin C, 40 mg epirubicin, 300 mg carboplatin)
Trial: 14560892
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment for early-stage endometriosis
Trial: 14560892
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment for moderate and severe endometriosis
Trial: 14560892
Drug: Medical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical treatment inducing an anovulatory state
Trial: 10964269
Drug: Indoor residual
RxNorm normalized name: Cleartime Indoor & Outdoor Allergies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indoor residual spraying with alphacypermethrin (Fendona) at 25 mg/m2
Trial: 10964269
Drug: Indoor residual
RxNorm normalized name: Cleartime Indoor & Outdoor Allergies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indoor residual spraying with suspension concentrate (SC) formulation
Trial: 8829929
Drug: Topical administration
RxNorm normalized name: Octocaine 5 % Ointment for Oral and Topical Administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical administration of 1 mg kg‐1 lignocaine 2% to the medial part of the eye after induction of anaesthesia (Group II)
Trial: 8829929
Drug: Topical administration
RxNorm normalized name: Octocaine 5 % Ointment for Oral and Topical Administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical administration of lignocaine after a 5 min interval (Group III)
Trial: 1392493
Drug: Rose Shu‐Xin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rose Shu‐Xin oral liquid
Trial: 1392493
Drug: Salvia miltiorrhiza
RxNorm normalized name: SALVIA MILTIORRHIZA ROOT
DrugBank: Salvia miltiorrhiza root (DB14337)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salvia miltiorrhiza tablet
Trial: 2414590
Drug: Verapamil 160
RxNorm normalized name: verapamil 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil 160 mg
Trial: 2414590
Drug: Calcium antagonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium antagonists (general)
Trial: 27346728
Drug: Brivaracetam 10
RxNorm normalized name: brivaracetam 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brivaracetam 10 mg tablet
Trial: 27346728
Drug: Brivaracetam 75
RxNorm normalized name: brivaracetam 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brivaracetam 75 mg tablet
Trial: 27346728
Drug: Brivaracetam 100
RxNorm normalized name: brivaracetam 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brivaracetam 100 mg tablet
Trial: 27346728
Drug: Brivaracetam 100
RxNorm normalized name: brivaracetam 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brivaracetam 100 mg intravenous bolus
Trial: 27346728
Drug: Brivaracetam 50
RxNorm normalized name: brivaracetam 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brivaracetam 50 mg tablet
Trial: 25891548
Drug: Low-dose PDA-001
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose PDA-001 (150×10(6) cells)
Trial: 25891548
Drug: High-dose PDA-001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose PDA-001 (600×10(6) cells)
Trial: 20727735
Drug: ECC+P (Epirubicin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ECC+P (Epirubicin, Cisplatin, Capecitabine + Pravastatin 40 mg once daily)
Trial: 31734798
Drug: Medication Management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication Management Service (MMS)
Trial: 26394882
Drug: tiotropium (18 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tiotropium (18 μg once daily) + budesonide/formoterol (160/4.5 μg 2 inhalations twice daily)
Trial: 26394882
Drug: tiotropium alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tiotropium alone (18 μg once daily)
Trial: 18485132
Drug: Torasemide prolonged
RxNorm normalized name: torasemide
DrugBank: Torasemide (DB00214)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Torasemide prolonged release (PR) 5 mg/day (uptitration to 10 mg/day if no response at 4 or 8 weeks)
Trial: 18485132
Drug: Torasemide immediate
RxNorm normalized name: torasemide
DrugBank: Torasemide (DB00214)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Torasemide immediate release (IR) 5 mg/day (uptitration to 10 mg/day if no response at 4 or 8 weeks)
Trial: 16181001
Drug: 200 microg
RxNorm normalized name: Digoxin 200 microgram oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 microg budesonide inhaled from a Respimat Soft Mist Inhaler (Respimat SMI)
Trial: 16181001
Drug: 200 microg
RxNorm normalized name: Digoxin 200 microgram oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 microg budesonide inhaled from a Turbuhaler dry powder inhaler (Turbuhaler DPI) with fast inhaled flow rate
Trial: 16181001
Drug: 200 microg
RxNorm normalized name: Digoxin 200 microgram oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 microg budesonide inhaled from a Turbuhaler dry powder inhaler (Turbuhaler DPI) with slow inhaled flow rate
Trial: 16181001
Drug: 250 microg
RxNorm normalized name: Digoxin 250 microgram oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 microg beclomethasone dipropionate inhaled from a pressurized metered dose inhaler (Becloforte pMDI)
Trial: 12774138
Drug: Topical nitroglycerine
RxNorm normalized name: nitroglycerin Topical Ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical nitroglycerine ointment (NGO) applied 10 minutes prior to heelstick
Trial: 12774138
Drug: Placebo ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo ointment applied 10 minutes prior to heelstick
Trial: 12774138
Drug: Topical nitroglycerine
RxNorm normalized name: nitroglycerin Topical Ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical nitroglycerine ointment (NGO)
Trial: 7982419
Drug: Controlled-release, prostacyclin-sparing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled-release, prostacyclin-sparing aspirin 75 mg daily plus anticoagulation (intravenous heparin followed by warfarin)
Trial: 7982419
Drug: Conventional aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional aspirin 75 mg daily plus anticoagulation (intravenous heparin followed by warfarin)
Trial: 3338726
Drug: Experimental residential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental residential treatment program
Trial: 5762643
Drug: Live attenuated
RxNorm normalized name: mumps, live attenuated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live attenuated rubella vaccines
Trial: 23981507
Drug: Web-based coaching
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Web-based coaching program with education, motivation, exercise guidance, daily SMS reminders, weekly feedback, and active monitoring by general practitioners.
Trial: 21346383
Drug: Preoperative CRT
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative CRT (45 Gy with chemotherapy)
Trial: 21346383
Drug: Postoperative CRT
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative CRT (45‐51 Gy with chemotherapy)
Trial: 16597076
Drug: Beclate and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclate and Qvar at higher doses
Trial: 12569265
Drug: HCT (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HCT (25 mg once daily for 9 days)
Trial: 12569265
Drug: HCT +
RxNorm normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: HCT + LOS (50 mg twice daily for 9 days)
Trial: 11050587
Drug: Tazarotene 0.1%
RxNorm normalized name: TAZAROTENE 0.1% GEL,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tazarotene 0.1% gel plus UVB phototherapy
Trial: 11050587
Drug: Vehicle gel
RxNorm normalized name: vehicle gel base no.61
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle gel plus UVB phototherapy
Trial: 27252432
Drug: Hylan G-F
RxNorm normalized name: hylan G-F 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hylan G-F 20 (6 mL)
Trial: 27252432
Drug: Triamcinolone acetonide
RxNorm normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triamcinolone acetonide (1 mL of 40-mg + 5 mL of 1% lidocaine with epinephrine)
Trial: 25708913
Drug: everolimus targeting
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: everolimus targeting 3-8 ng/ml with reduced-exposure cyclosporine (CsA)
Trial: 25708913
Drug: everolimus targeting
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: everolimus targeting 6-12 ng/ml with reduced-exposure cyclosporine (CsA)
Trial: 23739514
Drug: Levetiracetam (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levetiracetam (60 mg/kg/day for one year)
Trial: 20687400
Drug: Metformin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (500 mg/day) administered for 8 to 12 weeks before and during ovarian stimulation
Trial: 9839106
Drug: Metformin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (500 mg/day)
Trial: 8656661
Drug: Enalapril 20
RxNorm normalized name: enalapril 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril 20 mg as monotherapy
Trial: 8656661
Drug: Enalapril 20
RxNorm normalized name: enalapril 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril 20 mg plus hydrochlorothiazide (HCTZ 12.5 mg)
Trial: 8656661
Drug: Hydrochlorothiazide (HCTZ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (HCTZ 12.5 mg) alone
Trial: 6127964
Drug: Oral low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral low-dose combination of theophylline (280 mg) and terbutaline (2.5 mg)
Trial: 6127964
Drug: High oral
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High oral dose of terbutaline (5 mg)
Trial: 6127964
Drug: Inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of beta 2-adrenostimulant (1.25 mg terbutaline sulphate)
Trial: 19747435
Drug: Oral pinaverium
RxNorm normalized name: pinaverium
DrugBank: Pinaverium (DB09090)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral pinaverium (Control)
Trial: 17059993
Drug: beta-blocker, metoprolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: beta-blocker, metoprolol
Trial: 17059993
Drug: angiotensin-converting enzyme
RxNorm normalized name: ACE - Angiotensin-converting enzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: angiotensin-converting enzyme inhibitor, ramipril
Trial: 17059993
Drug: dihydropyridine calcium
RxNorm normalized name: 4-(2'-Nitrophenyl)-2,6-dimethyl-1,4-dihydropyridin-3,5-dicarbonsäuredimethylester
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dihydropyridine calcium channel blocker, amlodipine
Trial: 17059993
Drug: usual-blood pressure
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: usual-blood pressure treatment goal
Trial: 17059993
Drug: low-blood pressure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: low-blood pressure treatment goal
Trial: 12969086
Drug: Use of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of non-steroidal anti-inflammatory drugs
Trial: 11482713
Drug: Dobutamine stress
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dobutamine stress (start dose 5 microg/kg/min to maximum dose 15 microg/kg/min)
Trial: 1312002
Drug: Quinapril 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinapril 2.5 mg
Trial: 1312002
Drug: Quinapril 5
RxNorm normalized name: quinapril 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinapril 5 mg
Trial: 1312002
Drug: Quinapril 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinapril 0.5 mg
Trial: 1312002
Drug: All doses
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All doses of Quinapril
Trial: 1312002
Drug: Doses above
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doses above 2.5 mg of Quinapril
Trial: 2858217
Drug: Propoxyphene (65
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propoxyphene (65 mg every 6 h) with Alprazolam (1.0 mg orally)
Trial: 2858217
Drug: Propoxyphene (65
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propoxyphene (65 mg every 6 h) with Diazepam (10 mg i.v.)
Trial: 2858217
Drug: Propoxyphene (65
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propoxyphene (65 mg every 6 h) with Lorazepam (2 mg i.v.)
Trial: 31239321
Drug: Investigator's choice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigator's choice (IC) of single-agent chemotherapy
Trial: 23684618
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no treatment, Group E)
Trial: 19685375
Drug: n-3 polyunsaturated
RxNorm normalized name: Omega-3 (n-3) polyunsaturated fatty acids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-3 polyunsaturated fatty acids (n-3 PUFAs) - 2 capsules of Omacor twice daily
Trial: 19685375
Drug: Placebo -
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo - 2 capsules of placebo
Trial: 11177210
Drug: High-flavonol (HF)
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-flavonol (HF) diet including one 150 g onion cake (89.7 mg quercetin) and one 300 ml cup of black tea (1.4 mg quercetin) daily for 14 days
Trial: 9091008
Drug: Topical anaesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical anaesthesia (2 ml of 2% mepivacaine)
Trial: 3532315
Drug: Regular treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular treatment with inhaled salbutamol (400 micrograms qds)
Trial: 3532315
Drug: Irregular treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irregular treatment with inhaled salbutamol (400 micrograms prn)
Trial: 24832687
Drug: Structured conversation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structured conversation about patient goals and preferences for medical treatment